Internal request:
Panel request to review the data from the two published Phase III trials of bevacizumab in the primary treatment of ovarian cancer.

External request:
Submission from Genentech Inc. to consider recent publication of two pivotal, Phase III studies involving the study of bevacizumab in patients with previously untreated, advanced epithelial ovarian, primary peritoneal or fallopian tube cancer for your updating purposes.

<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion</th>
<th>References</th>
<th>Vote</th>
</tr>
</thead>
</table>